Stellanova Therapeutics, Inc. (“Stellanova”), a biotechnology company advancing cancer therapies targeting the tumor microenvironment, today announced the closing of a $15.5 million Series A financing led by Sporos Bioventures, LLC.  The funds will advance Stellanova’s lead antibody asset to first-in-human clinical trials for oncology, establish its discovery platform, and build its team.

Stellanova News

We use cookies to personalize your experience. By using our website you agree to our terms and conditions and privacy policy.